102 related articles for article (PubMed ID: 15775356)
1. [Renal failure and vitamin D].
Brown AJ; Dusso AS; Slatopolsky E
Clin Calcium; 2002 Jun; 12(6):711-23. PubMed ID: 15775356
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D analogues for secondary hyperparathyroidism.
Brown AJ; Dusso AS; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D analogs: perspectives for treatment.
Brown AJ; Slatopolsky E
Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
Brown AJ; Coyne DW
Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
[TBL] [Abstract][Full Text] [Related]
6. [A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone secretion and calcemic action].
Endo K; Fukagawa M
Clin Calcium; 2002 Jun; 12(6):737-40. PubMed ID: 15775359
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D3 polyunsaturated side-chain analogues (EB1089, GS1590) and the 20-epi-vitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells.
Segersten U; Holm PK; Binderup L; Akerström G; Hellman P; Westin G
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):289-94. PubMed ID: 15120422
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
9. Bone disease in uremic patients: advances in PTH suppression.
Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
[TBL] [Abstract][Full Text] [Related]
10. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
12. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
[TBL] [Abstract][Full Text] [Related]
13. New strategies for the treatment of secondary hyperparathyroidism.
Akizawa T; Shiizaki K; Hatamura I; Kamimura M; Mizobuchi M; Narukawa N; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S100-3. PubMed ID: 12612963
[TBL] [Abstract][Full Text] [Related]
14. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure.
Dusso A; Cozzolino M; Lu Y; Sato T; Slatopolsky E
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):507-11. PubMed ID: 15225829
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
Brown AJ; Slatopolsky E
Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D physiology.
Lips P
Prog Biophys Mol Biol; 2006 Sep; 92(1):4-8. PubMed ID: 16563471
[TBL] [Abstract][Full Text] [Related]
17. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo.
Brown AJ; Ritter CS; Holliday LS; Knutson JC; Strugnell SA
Biochem Pharmacol; 2004 Oct; 68(7):1289-96. PubMed ID: 15345318
[TBL] [Abstract][Full Text] [Related]
19. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion.
Brown AJ; Ritter CS; Weiskopf AS; Vouros P; Sasso GJ; Uskokovic MR; Wang G; Reddy GS
J Cell Biochem; 2005 Oct; 96(3):569-78. PubMed ID: 16088954
[TBL] [Abstract][Full Text] [Related]
20. [Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease].
Malluche HH; Kubodera N
Clin Calcium; 2002 Jun; 12(6):724-9. PubMed ID: 15775357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
